Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Advancing glioblastoma treatment options: viral therapy, LIIT and immunotherapy

Andrew Sloan, MD, Case Western Reserve University, Cleveland, OH, talks on the latest approaches under investigation for the treatment of glioblastoma. Oncolytic viral therapy is an exciting novel strategy, with numerous ongoing clinical trials. Glioblastoma is an aggressive cancer with poor overall survival and no standard of care in the recurrent setting. Viral therapies such as PVSRIPO are among the first to demonstrate a survival benefit, giving them the potential to change clinical practice with further development. Immunotherapy-based approaches are also gaining attention. For example, trials are assessing immunotherapy in combination with radiotherapy or laser interstitial thermal therapy (LITT). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.